Drug Trial Radar · NCT01254279
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Last checked: Nov 19, 2026Latest source record: Jan 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
984
Actual
Start
Dec 2010
Primary completion
Dec 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 6, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial (NCT00417079), and Investigators access to cabazitaxel for the management of metastatic Hormone Refractory Prostate Cancer (mHRPC) in those patients who have progressed during or after docetaxel and to document the overall safety of cabazitaxel in these patients. Please note that in each country, patient recruitment will end when cabazitaxel becomes commercially available.
Conditions
- Prostate Cancer Metastatic
Interventions
CABAZITAXELDrug
Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- To provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimenTime frame: Up to 30 weeks
Locations
165 sites in 29 countries. Site status is shown where the registry gives one.
Investigational Site Number 036004
Box Hill, Australia
Investigational Site Number 036020
Campbelltown, Australia
Investigational Site Number 036001
Camperdown, Australia
Investigational Site Number 036002
Camperdown, Australia
Investigational Site Number 036011
Douglas, Australia
Investigational Site Number 036019
Nambour, Australia
Investigational Site Number 036023
North Adelaide, Australia
Investigational Site Number 036008
Parkville, Australia
Investigational Site Number 036005
Perth, Australia
Investigational Site Number 036003
Port Macquarie, Australia
Investigational Site Number 036025
Randwick, Australia
Investigational Site Number 036009
South Brisbane, Australia
Investigational Site Number 036022
South Brisbane, Australia
Investigational Site Number 036017
Southport, Australia
Investigational Site Number 036012
St Leonards, Australia
Investigational Site Number 036010
Sydney, Australia
Investigational Site Number 036013
Sydney, Australia
Investigational Site Number 036014
Sydney, Australia
Investigational Site Number 036016
Tweed Heads, Australia
Investigational Site Number 036024
Wendouree, Australia
Investigational Site Number 036007
Westmead, Australia
Investigational Site Number 036015
Wodonga, Australia
Investigational Site Number 040-004
Linz, Austria
Investigational Site Number 040-005
Salzburg, Austria
Investigational Site Number 040-002
Vienna, Austria
Investigational Site Number 040-003
Vienna, Austria
Investigational Site Number 056002
Bruges, Belgium
Investigational Site Number 056007
Brussels, Belgium
Investigational Site Number 056003
Haine-Saint-Paul, Belgium
Investigational Site Number 056005
Liège, Belgium
Investigational Site Number 056004
Ottignies, Belgium
Investigational Site Number 056001
Roeselare, Belgium
Investigational Site Number 056006
Tournai, Belgium
Investigational Site Number 070003
Banja Luka, Bosnia and Herzegovina
Investigational Site Number 070001
Sarajevo, Bosnia and Herzegovina
Investigational Site Number 070002
Zenica, Bosnia and Herzegovina
Investigational Site Number 100004
Plovdiv, Bulgaria
Investigational Site Number 100001
Sofia, Bulgaria
Investigational Site Number 100003
Sofia, Bulgaria
Investigational Site Number 100002
Sofia, Bulgaria
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.